Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRNX Crinetics Pharmaceuticals	$33.76 +0.7%	$32.17	$24.10 ▼ $62.53	$3.16B	0.37	861,252 shs	907,545 shs
GYRE Gyre Therapeutics	$9.26 -0.9%	$9.28	$6.11 ▼ $19.00	$868.06M	1.9	93,158 shs	132,315 shs
MRUS Merus	$44.19 -2.8%	$43.96	$33.19 ▼ $61.61	$3.14B	0.94	712,091 shs	705,630 shs
OGN Organon & Co.	$9.60 +1.6%	$13.46	$9.18 ▼ $23.10	$2.50B	0.73	2.90 million shs	13.58 million shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRNX Crinetics Pharmaceuticals	+0.72%	+4.23%	+7.55%	-16.23%	-25.06%
GYRE Gyre Therapeutics	-0.86%	+2.09%	+30.61%	-19.55%	-33.19%
MRUS Merus	-2.77%	+1.42%	+2.74%	+7.94%	-6.02%
OGN Organon & Co.	+1.69%	-21.38%	-34.87%	-38.40%	-49.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRNX Crinetics Pharmaceuticals	3.7856 of 5 stars	3.5	1.0	0.0	3.7	3.7	2.5	0.0
GYRE Gyre Therapeutics	0.0194 of 5 stars	0.0	0.0	0.0	0.0	0.0	1.7	0.0
MRUS Merus	3.4109 of 5 stars	4.6	3.0	0.0	0.0	3.8	1.7	0.0
OGN Organon & Co.	4.7313 of 5 stars	3.0	1.0	3.3	3.7	3.1	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRNX Crinetics Pharmaceuticals	2.92	Moderate Buy	$73.00	116.23% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
MRUS Merus	3.13	Buy	$85.31	93.05% Upside
OGN Organon & Co.	2.00	Hold	$19.67	104.86% Upside

Current Analyst Ratings Breakdown

Latest GYRE, OGN, MRUS, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/2/2025	OGN Organon & Co.	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline
4/28/2025	MRUS Merus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/9/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$83.00 ➝ $83.00
4/9/2025	OGN Organon & Co.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$16.00 ➝ $15.00
3/28/2025	MRUS Merus	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$109.00 ➝ $109.00
3/25/2025	CRNX Crinetics Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
3/18/2025	MRUS Merus	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$109.00 ➝ $109.00
3/11/2025	GYRE Gyre Therapeutics	Noble Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
3/10/2025	MRUS Merus	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$73.00 ➝ $70.00
3/3/2025	MRUS Merus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$85.00 ➝ $85.00
2/28/2025	MRUS Merus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRNX Crinetics Pharmaceuticals	$1.04M	3,042.27	N/A	N/A	$8.07 per share	4.18
GYRE Gyre Therapeutics	$105.76M	8.21	$0.18 per share	50.49	$0.18 per share	51.44
MRUS Merus	$36.13M	84.61	N/A	N/A	$6.17 per share	7.16
OGN Organon & Co.	$6.40B	0.39	$3.08 per share	3.12	($0.27) per share	-35.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRNX Crinetics Pharmaceuticals	-$214.53M	-$3.71	N/A	N/A	N/A	N/A	-36.12%	-31.89%	5/8/2025 (Estimated)
GYRE Gyre Therapeutics	-$92.93M	$0.05	185.20	∞	N/A	-84.57%	-118.43%	-71.97%	5/8/2025 (Estimated)
MRUS Merus	-$154.94M	-$3.27	N/A	N/A	N/A	-680.61%	-38.89%	-31.16%	5/6/2025 (Estimated)
OGN Organon & Co.	$864M	$3.33	2.88	2.57	0.90	13.49%	431.62%	8.03%	N/A

Latest GYRE, OGN, MRUS, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MRUS Merus	-$1.17	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	CRNX Crinetics Pharmaceuticals	-$0.99	N/A	N/A	N/A	$0.10 million	N/A
5/8/2025	Q1 2025	GYRE Gyre Therapeutics	$0.03	N/A	N/A	N/A	$28.40 million	N/A
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion
3/17/2025	Q4 2024	GYRE Gyre Therapeutics	$0.04	$0.01	-$0.03	$0.02	$23.50 million	$27.87 million
2/27/2025	Q4 2024	CRNX Crinetics Pharmaceuticals	-$0.92	-$0.88	+$0.04	-$0.88	$0.73 million	N/A
2/27/2025	Q4 2024	MRUS Merus	-$0.89	-$0.41	+$0.48	-$0.41	$10.57 million	$9.14 million
2/13/2025	Q4 2024	OGN Organon & Co.	$0.92	$0.83	-$0.09	$0.42	$1.57 billion	$1.59 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$1.12	11.67%	+25.99%	33.63%	N/A

Latest GYRE, OGN, MRUS, and CRNX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025
2/13/2025	OGN Organon & Co.	quarterly	$0.28	7.3%	2/24/2025	2/24/2025	3/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRNX Crinetics Pharmaceuticals	N/A	16.39	16.38
GYRE Gyre Therapeutics	N/A	3.72	3.29
MRUS Merus	N/A	8.32	8.32
OGN Organon & Co.	17.73	1.70	1.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRNX Crinetics Pharmaceuticals	98.51%
GYRE Gyre Therapeutics	23.99%
MRUS Merus	96.14%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
CRNX Crinetics Pharmaceuticals	6.00%
GYRE Gyre Therapeutics	19.52%
MRUS Merus	4.57%
OGN Organon & Co.	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRNX Crinetics Pharmaceuticals	210	93.63 million	87.17 million	Optionable
GYRE Gyre Therapeutics	40	93.74 million	75.27 million	No Data
MRUS Merus	37	69.18 million	65.34 million	Optionable
OGN Organon & Co.	10,000	259.96 million	253.93 million	Not Optionable

GYRE, OGN, MRUS, and CRNX Headlines

Recent News About These Companies

Organon & Co. Sees Unusually Large Options Volume (NYSE:OGN)

May 3 at 2:56 AM | americanbankingnews.com

Organon & Co (OGN) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Revenue Challenges

May 3 at 1:10 AM | finance.yahoo.com

Brokerages Set Organon & Co. (NYSE:OGN) PT at $19.75

May 3 at 1:09 AM | americanbankingnews.com

OGN INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Organon & Co. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

May 2 at 6:37 PM | globenewswire.com

Why The Low Payout Ratio Did Not Stop The Dividend Cut For Organon

May 2 at 10:12 AM | seekingalpha.com

Organon & Co. (NYSE:OGN) Stake Raised by Stifel Financial Corp

May 2 at 4:26 AM | marketbeat.com

Organon & Co. (NYSE:OGN) Given Consensus Recommendation of "Hold" by Brokerages

May 2 at 4:24 AM | marketbeat.com

Organon & Co. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OGN

May 1 at 3:20 PM | businesswire.com

OGN Investors Have Opportunity to Join Organon & Co. Fraud Investigation with the Schall Law Firm

May 1 at 2:55 PM | businesswire.com

Organon & Co. (OGN) Q1 2025 Earnings Call Transcript

May 1 at 12:05 PM | seekingalpha.com

Organon stock falls as revenue misses estimates, guidance disappoints

May 1 at 11:37 AM | investing.com

Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say

May 1 at 11:35 AM | zacks.com

Organon & Co. 2025 Q1 - Results - Earnings Call Presentation

May 1 at 11:33 AM | seekingalpha.com

Organon (OGN) Q1 Earnings Surpass Estimates

May 1 at 9:10 AM | zacks.com

Susquehanna Fundamental Investments LLC Invests $4.85 Million in Organon & Co. (NYSE:OGN)

May 1 at 5:56 AM | marketbeat.com

Organon Q1 2025 Earnings Preview

April 30 at 6:36 PM | msn.com

Organon & Co. (NYSE:OGN) Trading 4.6% Higher - Time to Buy?

April 30 at 2:11 PM | marketbeat.com

Boothbay Fund Management LLC Raises Holdings in Organon & Co. (NYSE:OGN)

April 30 at 6:21 AM | marketbeat.com

Oxford Asset Management LLP Invests $419,000 in Organon & Co. (NYSE:OGN)

April 29, 2025 | marketbeat.com

Raymond James Financial Inc. Invests $4.19 Million in Organon & Co. (NYSE:OGN)

April 29, 2025 | marketbeat.com

Countdown to Organon (OGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

April 28, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE, OGN, MRUS, and CRNX Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

$33.76 +0.24 (+0.72%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$33.77 +0.01 (+0.03%)

As of 05/2/2025 04:20 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Gyre Therapeutics NASDAQ:GYRE

$9.26 -0.08 (-0.86%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$9.26 0.00 (-0.05%)

As of 05/2/2025 05:19 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Merus NASDAQ:MRUS

$44.19 -1.26 (-2.77%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$46.32 +2.13 (+4.82%)

As of 05/2/2025 07:57 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Organon & Co. NYSE:OGN

$9.60 +0.15 (+1.59%)

Closing price 05/2/2025 03:59 PM Eastern

Extended Trading

$9.56 -0.04 (-0.36%)

As of 05/2/2025 07:59 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time